Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $488000.0.

  • Cytosorbents' Share-based Compensation fell 4523.01% to $488000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 3795.3%. This contributed to the annual value of $3.8 million for FY2024, which is 952.53% down from last year.
  • As of Q3 2025, Cytosorbents' Share-based Compensation stood at $488000.0, which was down 4523.01% from $571000.0 recorded in Q2 2025.
  • Over the past 5 years, Cytosorbents' Share-based Compensation peaked at $1.7 million during Q4 2023, and registered a low of $488000.0 during Q3 2025.
  • Moreover, its 5-year median value for Share-based Compensation was $869908.0 (2022), whereas its average is $907121.6.
  • In the last 5 years, Cytosorbents' Share-based Compensation crashed by 5115.53% in 2022 and then soared by 9178.37% in 2023.
  • Cytosorbents' Share-based Compensation (Quarter) stood at $796745.0 in 2021, then grew by 9.18% to $869908.0 in 2022, then soared by 91.78% to $1.7 million in 2023, then plummeted by 44.88% to $919534.0 in 2024, then plummeted by 46.93% to $488000.0 in 2025.
  • Its last three reported values are $488000.0 in Q3 2025, $571000.0 for Q2 2025, and $818426.0 during Q1 2025.